Increase in the understanding of diseases and research into the development of new drugs for non-small cell lung cancer is fueling the market growth.
Market Size – USD 6.45 Billion in 2018, Market Growth - CAGR of 6.2%, Market Trends – The rise in the prevalence of lung cancer.
NEW YORK, June 05, 2019 (GLOBE NEWSWIRE) -- The Global Non-Small Cell Lung Cancer Market is forecast to reach USD 10.53 Billion by 2026, according to a new report by Reports and Data. Non-small cell lung cancer accounts for approximately 85% of all lung cancers.
The rise in the number of people suffering from non-small cell lung cancer is one of the major factors driving the global non-small cell lung cancer drugs market growth. The risk factors such as air pollution, cigarette smoking, passive smoking, and occupational exposure are increasing the incidence of the disease globally.
One of the major drivers of the non-small cell lung cancer is the strong drug pipeline and recent drug approvals. The innovation of new drugs and their approvals for the treatment of the disease is anticipated to fuel the growth of the market.
Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/14755
One of the challenges of the non-small cell lung cancer market is the high cost of treatment. The disease can be treated by chemotherapy, surgery, targeted therapies, radiation therapy, and immunotherapy, which is quite expensive. Thus, the high cost of the treatment will hamper the growth of the market.
Further key findings from the report suggest
- Smoking causes ~90% of lung cancer cases. Constant exposure to the high level of air pollution and drinking water with a high level of arsenic increases the odds of lung cancer.
- The most common type of non-small cell lung cancer are adenocarcinomas, squamous cell carcinoma, and large cell carcinomas.
- Squamous cell carcinoma is the second most common form of lung cancer. This type of lung cancer is found in the middle of the lungs. It is forecasted to hold a market share of 37% in the year 2026.
- Adenocarcinoma held a market share of 48% in the year 2018. The disease tends to develop in smaller airways such as bronchioles, breasts, prostate, pancreas, and colon.
- Adenocarcinoma accounts for approximately more than 40% of lung cancer and is found mostly in women and grows more slowly than any other cancers.
- Surgery is expected to grow at a CAGR of 6.8% during the forecast period. It is an option to be performed at an early stage and is the best chance to cure the disease.
- Types of lung cancer surgeries include pneumonectomy, lobectomy, segmentectomy or wedge resection, and sleeve resection.
- Chemotherapy is a treatment with anti-cancer drugs that are injected into a vein or taken by mouth. The treatment is useful for treating cancer anywhere in the body.
- Doctors recommend chemotherapy in combination with definitive radiation treatments for patients with stage III lung cancer that cannot be removed surgically. In stage IV, radiation is used only for palliation of the symptoms.
- Angiogenesis inhibitor is a substance that inhibits the growth off new blood vessels. It held a market share of 16% in the year 2018.
- The market in Asia Pacific is anticipated to be the leading contributor in the non-small cell lung cancer market. Rising awareness regarding cancer and initiatives taken by the governments in the region to encourage the treatment of lung cancer through medicines in public healthcare centers and subsidized treatment will fuel the market growth.
- Key participants include Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. among others.
To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/non-small-cell-lung-cancer-market
Segments covered in the report:
For the purpose of this report, Reports and Data have segmented the global Non-Small Cell Lung Cancer Market on the basis of Histology, Treatment, Drug Class, and Region:
Histology Outlook (Revenue, USD Billion; 2016-2026)
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Adenocarcinoma
Treatment Outlook (Revenue, USD Billion; 2016-2026)
- Surgery
- Radiation
- Chemotherapy
- Targeted Therapy Drugs
Drug Class Outlook (Revenue, USD Billion; 2016-2026)
- Angiogenesis Inhibitor
- Epidermal Growth Factor Receptor Blocker
- Kinase Inhibitor
- Microtubule Stabilizer
- Folate Antimetabolites
- PD-1/ PD-L1 Inhibitor
Order Now: https://www.reportsanddata.com/checkout-form/1475
Regional Outlook (Revenue in USD Million; 2016–2026)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
- Brazil
Browse more reports of Pharmaceutical category at: https://www.reportsanddata.com/report/category/pharmaceutical
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John Watson
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-800-819-3052
E-mail: sales@reportsanddata.com